Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer

NCT01936363 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Pimasertib once daily
DRUG: Pimasertib placebo
DRUG: SAR245409 placebo
DRUG: SAR245409
DRUG: Pimasertib twice daily

Sponsor

EMD Serono

Collaborators

[object Object]